nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—Vinblastine—head and neck cancer	0.61	0.81	CbGbCtD
Irbesartan—CYP2D6—Hydroxyurea—head and neck cancer	0.0441	0.0586	CbGbCtD
Irbesartan—CYP2C8—Fluorouracil—head and neck cancer	0.0264	0.0351	CbGbCtD
Irbesartan—CYP1A2—Fluorouracil—head and neck cancer	0.0204	0.0272	CbGbCtD
Irbesartan—CYP2C9—Fluorouracil—head and neck cancer	0.0184	0.0245	CbGbCtD
Irbesartan—CYP2D6—Vinblastine—head and neck cancer	0.0156	0.0207	CbGbCtD
Irbesartan—CYP3A4—Vinblastine—head and neck cancer	0.00992	0.0132	CbGbCtD
Irbesartan—CYP3A4—Docetaxel—head and neck cancer	0.00818	0.0109	CbGbCtD
Irbesartan—Erythema facial—Hydroxyurea—head and neck cancer	0.0055	0.0574	CcSEcCtD
Irbesartan—Common cold—Fluorouracil—head and neck cancer	0.00277	0.0289	CcSEcCtD
Irbesartan—Gastric irritation—Hydroxyurea—head and neck cancer	0.00259	0.0271	CcSEcCtD
Irbesartan—Epigastric discomfort—Hydroxyurea—head and neck cancer	0.00191	0.02	CcSEcCtD
Irbesartan—JUN—exocrine gland—head and neck cancer	0.00157	0.101	CbGeAlD
Irbesartan—Numbness—Vinblastine—head and neck cancer	0.00133	0.0139	CcSEcCtD
Irbesartan—Sensory loss—Vinblastine—head and neck cancer	0.00127	0.0133	CcSEcCtD
Irbesartan—JUN—mouth—head and neck cancer	0.00117	0.0757	CbGeAlD
Irbesartan—Tenderness—Hydroxyurea—head and neck cancer	0.00115	0.012	CcSEcCtD
Irbesartan—Bone pain—Vinblastine—head and neck cancer	0.00115	0.012	CcSEcCtD
Irbesartan—Raised liver function tests—Docetaxel—head and neck cancer	0.00113	0.0118	CcSEcCtD
Irbesartan—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.00108	0.0113	CcSEcCtD
Irbesartan—Heartburn—Fluorouracil—head and neck cancer	0.00105	0.011	CcSEcCtD
Irbesartan—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00102	0.0107	CcSEcCtD
Irbesartan—Lymphopenia—Docetaxel—head and neck cancer	0.00102	0.0107	CcSEcCtD
Irbesartan—JUN—neck—head and neck cancer	0.001	0.0647	CbGeAlD
Irbesartan—Blood urea increased—Hydroxyurea—head and neck cancer	0.000948	0.0099	CcSEcCtD
Irbesartan—Pulmonary oedema—Hydroxyurea—head and neck cancer	0.000893	0.00934	CcSEcCtD
Irbesartan—Numbness—Fluorouracil—head and neck cancer	0.000872	0.00911	CcSEcCtD
Irbesartan—Sensory loss—Fluorouracil—head and neck cancer	0.000834	0.00872	CcSEcCtD
Irbesartan—Tenderness—Fluorouracil—head and neck cancer	0.000828	0.00866	CcSEcCtD
Irbesartan—JUN—parotid gland—head and neck cancer	0.000817	0.0527	CbGeAlD
Irbesartan—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000815	0.00852	CcSEcCtD
Irbesartan—JUN—saliva-secreting gland—head and neck cancer	0.000783	0.0505	CbGeAlD
Irbesartan—Heartburn—Docetaxel—head and neck cancer	0.000758	0.00792	CcSEcCtD
Irbesartan—AGTR1—neck—head and neck cancer	0.000756	0.0487	CbGeAlD
Irbesartan—JUN—connective tissue—head and neck cancer	0.000719	0.0464	CbGeAlD
Irbesartan—Face oedema—Hydroxyurea—head and neck cancer	0.000703	0.00735	CcSEcCtD
Irbesartan—JUN—epithelium—head and neck cancer	0.000683	0.044	CbGeAlD
Irbesartan—Angina pectoris—Vinblastine—head and neck cancer	0.000673	0.00703	CcSEcCtD
Irbesartan—EDNRA—trachea—head and neck cancer	0.000662	0.0427	CbGeAlD
Irbesartan—Oesophagitis—Fluorouracil—head and neck cancer	0.00066	0.0069	CcSEcCtD
Irbesartan—Breast disorder—Hydroxyurea—head and neck cancer	0.000658	0.00688	CcSEcCtD
Irbesartan—Pancreatitis—Hydroxyurea—head and neck cancer	0.000617	0.00645	CcSEcCtD
Irbesartan—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000607	0.00634	CcSEcCtD
Irbesartan—JUN—trachea—head and neck cancer	0.000604	0.0389	CbGeAlD
Irbesartan—Myocardial infarction—Vinblastine—head and neck cancer	0.000604	0.00631	CcSEcCtD
Irbesartan—Photosensitivity—Fluorouracil—head and neck cancer	0.000597	0.00624	CcSEcCtD
Irbesartan—Swelling—Fluorouracil—head and neck cancer	0.000595	0.00621	CcSEcCtD
Irbesartan—Neutropenia—Hydroxyurea—head and neck cancer	0.000589	0.00615	CcSEcCtD
Irbesartan—Agranulocytosis—Vinblastine—head and neck cancer	0.000575	0.00601	CcSEcCtD
Irbesartan—Weight increased—Hydroxyurea—head and neck cancer	0.000573	0.00599	CcSEcCtD
Irbesartan—Drug interaction—Docetaxel—head and neck cancer	0.000562	0.00588	CcSEcCtD
Irbesartan—Hypoaesthesia—Vinblastine—head and neck cancer	0.00055	0.00575	CcSEcCtD
Irbesartan—Pharyngitis—Vinblastine—head and neck cancer	0.000549	0.00573	CcSEcCtD
Irbesartan—Bone pain—Docetaxel—head and neck cancer	0.000544	0.00569	CcSEcCtD
Irbesartan—AGTR1—connective tissue—head and neck cancer	0.000542	0.0349	CbGeAlD
Irbesartan—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000531	0.00555	CcSEcCtD
Irbesartan—JUN—lymphoid tissue—head and neck cancer	0.000526	0.0339	CbGeAlD
Irbesartan—EDNRA—thyroid gland—head and neck cancer	0.000524	0.0338	CbGeAlD
Irbesartan—Blood pressure increased—Docetaxel—head and neck cancer	0.000522	0.00545	CcSEcCtD
Irbesartan—AGTR1—epithelium—head and neck cancer	0.000514	0.0332	CbGeAlD
Irbesartan—JUN—thyroid gland—head and neck cancer	0.000478	0.0308	CbGeAlD
Irbesartan—Oesophagitis—Docetaxel—head and neck cancer	0.000477	0.00498	CcSEcCtD
Irbesartan—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000469	0.0049	CcSEcCtD
Irbesartan—Lightheadedness—Docetaxel—head and neck cancer	0.000467	0.00488	CcSEcCtD
Irbesartan—Pulmonary oedema—Docetaxel—head and neck cancer	0.000464	0.00485	CcSEcCtD
Irbesartan—Muscular weakness—Fluorouracil—head and neck cancer	0.000463	0.00483	CcSEcCtD
Irbesartan—Angiopathy—Hydroxyurea—head and neck cancer	0.000457	0.00478	CcSEcCtD
Irbesartan—AGTR1—trachea—head and neck cancer	0.000455	0.0293	CbGeAlD
Irbesartan—Dysphagia—Fluorouracil—head and neck cancer	0.000453	0.00474	CcSEcCtD
Irbesartan—Chills—Hydroxyurea—head and neck cancer	0.000452	0.00473	CcSEcCtD
Irbesartan—Ill-defined disorder—Vinblastine—head and neck cancer	0.000446	0.00467	CcSEcCtD
Irbesartan—Anaemia—Vinblastine—head and neck cancer	0.000445	0.00465	CcSEcCtD
Irbesartan—Angina pectoris—Fluorouracil—head and neck cancer	0.000442	0.00462	CcSEcCtD
Irbesartan—Erythema—Hydroxyurea—head and neck cancer	0.000439	0.00459	CcSEcCtD
Irbesartan—Malaise—Vinblastine—head and neck cancer	0.000434	0.00454	CcSEcCtD
Irbesartan—Vertigo—Vinblastine—head and neck cancer	0.000432	0.00452	CcSEcCtD
Irbesartan—Leukopenia—Vinblastine—head and neck cancer	0.000431	0.0045	CcSEcCtD
Irbesartan—Swelling—Docetaxel—head and neck cancer	0.000429	0.00448	CcSEcCtD
Irbesartan—JUN—head—head and neck cancer	0.000424	0.0273	CbGeAlD
Irbesartan—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000421	0.0044	CcSEcCtD
Irbesartan—Hypertension—Vinblastine—head and neck cancer	0.000415	0.00434	CcSEcCtD
Irbesartan—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000414	0.00432	CcSEcCtD
Irbesartan—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000407	0.00426	CcSEcCtD
Irbesartan—Pneumonia—Fluorouracil—head and neck cancer	0.000407	0.00425	CcSEcCtD
Irbesartan—Anaemia—Hydroxyurea—head and neck cancer	0.000406	0.00424	CcSEcCtD
Irbesartan—Discomfort—Vinblastine—head and neck cancer	0.000405	0.00423	CcSEcCtD
Irbesartan—Hot flush—Docetaxel—head and neck cancer	0.000405	0.00423	CcSEcCtD
Irbesartan—Menopausal symptoms—Docetaxel—head and neck cancer	0.000401	0.00419	CcSEcCtD
Irbesartan—Visual disturbance—Docetaxel—head and neck cancer	0.000399	0.00418	CcSEcCtD
Irbesartan—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000398	0.00416	CcSEcCtD
Irbesartan—Renal impairment—Docetaxel—head and neck cancer	0.000398	0.00416	CcSEcCtD
Irbesartan—Myocardial infarction—Fluorouracil—head and neck cancer	0.000396	0.00414	CcSEcCtD
Irbesartan—AGTR1—lymphoid tissue—head and neck cancer	0.000396	0.0255	CbGeAlD
Irbesartan—Malaise—Hydroxyurea—head and neck cancer	0.000396	0.00414	CcSEcCtD
Irbesartan—Urinary tract infection—Fluorouracil—head and neck cancer	0.000393	0.00411	CcSEcCtD
Irbesartan—Conjunctivitis—Fluorouracil—head and neck cancer	0.000393	0.00411	CcSEcCtD
Irbesartan—Leukopenia—Hydroxyurea—head and neck cancer	0.000393	0.00411	CcSEcCtD
Irbesartan—Thrombocytopenia—Vinblastine—head and neck cancer	0.000384	0.00402	CcSEcCtD
Irbesartan—Epistaxis—Fluorouracil—head and neck cancer	0.000381	0.00398	CcSEcCtD
Irbesartan—Hyponatraemia—Docetaxel—head and neck cancer	0.00038	0.00397	CcSEcCtD
Irbesartan—Agranulocytosis—Fluorouracil—head and neck cancer	0.000377	0.00394	CcSEcCtD
Irbesartan—Anorexia—Vinblastine—head and neck cancer	0.000374	0.00391	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000371	0.00388	CcSEcCtD
Irbesartan—Discomfort—Hydroxyurea—head and neck cancer	0.000369	0.00386	CcSEcCtD
Irbesartan—Rhinitis—Fluorouracil—head and neck cancer	0.000364	0.0038	CcSEcCtD
Irbesartan—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000361	0.00377	CcSEcCtD
Irbesartan—Pharyngitis—Fluorouracil—head and neck cancer	0.00036	0.00376	CcSEcCtD
Irbesartan—AGTR1—thyroid gland—head and neck cancer	0.00036	0.0232	CbGeAlD
Irbesartan—Oedema—Hydroxyurea—head and neck cancer	0.000358	0.00374	CcSEcCtD
Irbesartan—Infection—Hydroxyurea—head and neck cancer	0.000356	0.00372	CcSEcCtD
Irbesartan—Paraesthesia—Vinblastine—head and neck cancer	0.000353	0.00369	CcSEcCtD
Irbesartan—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000351	0.00367	CcSEcCtD
Irbesartan—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000351	0.00366	CcSEcCtD
Irbesartan—Liver function test abnormal—Docetaxel—head and neck cancer	0.000349	0.00365	CcSEcCtD
Irbesartan—Skin disorder—Hydroxyurea—head and neck cancer	0.000348	0.00364	CcSEcCtD
Irbesartan—Abdominal pain upper—Docetaxel—head and neck cancer	0.000346	0.00361	CcSEcCtD
Irbesartan—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000346	0.00361	CcSEcCtD
Irbesartan—Breast disorder—Docetaxel—head and neck cancer	0.000342	0.00358	CcSEcCtD
Irbesartan—Anorexia—Hydroxyurea—head and neck cancer	0.000341	0.00357	CcSEcCtD
Irbesartan—Decreased appetite—Vinblastine—head and neck cancer	0.000341	0.00357	CcSEcCtD
Irbesartan—Cramp muscle—Docetaxel—head and neck cancer	0.000341	0.00356	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000341	0.00356	CcSEcCtD
Irbesartan—Nasopharyngitis—Docetaxel—head and neck cancer	0.000339	0.00354	CcSEcCtD
Irbesartan—Pain—Vinblastine—head and neck cancer	0.000336	0.00351	CcSEcCtD
Irbesartan—Constipation—Vinblastine—head and neck cancer	0.000336	0.00351	CcSEcCtD
Irbesartan—Dysphagia—Docetaxel—head and neck cancer	0.000327	0.00342	CcSEcCtD
Irbesartan—EDNRA—lymph node—head and neck cancer	0.000325	0.021	CbGeAlD
Irbesartan—Arrhythmia—Fluorouracil—head and neck cancer	0.000324	0.00339	CcSEcCtD
Irbesartan—Feeling abnormal—Vinblastine—head and neck cancer	0.000324	0.00338	CcSEcCtD
Irbesartan—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000321	0.00336	CcSEcCtD
Irbesartan—Dyspnoea—Hydroxyurea—head and neck cancer	0.000319	0.00334	CcSEcCtD
Irbesartan—AGTR1—head—head and neck cancer	0.000319	0.0206	CbGeAlD
Irbesartan—Angina pectoris—Docetaxel—head and neck cancer	0.000319	0.00333	CcSEcCtD
Irbesartan—Somnolence—Hydroxyurea—head and neck cancer	0.000318	0.00333	CcSEcCtD
Irbesartan—Erythema—Fluorouracil—head and neck cancer	0.000316	0.0033	CcSEcCtD
Irbesartan—Dyspepsia—Hydroxyurea—head and neck cancer	0.000315	0.00329	CcSEcCtD
Irbesartan—Decreased appetite—Hydroxyurea—head and neck cancer	0.000311	0.00325	CcSEcCtD
Irbesartan—Abdominal pain—Vinblastine—head and neck cancer	0.00031	0.00324	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000309	0.00323	CcSEcCtD
Irbesartan—Fatigue—Hydroxyurea—head and neck cancer	0.000309	0.00323	CcSEcCtD
Irbesartan—Pain—Hydroxyurea—head and neck cancer	0.000306	0.0032	CcSEcCtD
Irbesartan—Constipation—Hydroxyurea—head and neck cancer	0.000306	0.0032	CcSEcCtD
Irbesartan—Neutropenia—Docetaxel—head and neck cancer	0.000306	0.0032	CcSEcCtD
Irbesartan—Weight increased—Docetaxel—head and neck cancer	0.000298	0.00311	CcSEcCtD
Irbesartan—Vision blurred—Fluorouracil—head and neck cancer	0.000298	0.00311	CcSEcCtD
Irbesartan—JUN—lymph node—head and neck cancer	0.000297	0.0191	CbGeAlD
Irbesartan—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000295	0.00308	CcSEcCtD
Irbesartan—Pneumonia—Docetaxel—head and neck cancer	0.000293	0.00307	CcSEcCtD
Irbesartan—Anaemia—Fluorouracil—head and neck cancer	0.000292	0.00305	CcSEcCtD
Irbesartan—Hypersensitivity—Vinblastine—head and neck cancer	0.000289	0.00302	CcSEcCtD
Irbesartan—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000288	0.00301	CcSEcCtD
Irbesartan—Renal failure—Docetaxel—head and neck cancer	0.000287	0.003	CcSEcCtD
Irbesartan—Myocardial infarction—Docetaxel—head and neck cancer	0.000286	0.00299	CcSEcCtD
Irbesartan—Jaundice—Docetaxel—head and neck cancer	0.000284	0.00297	CcSEcCtD
Irbesartan—Conjunctivitis—Docetaxel—head and neck cancer	0.000284	0.00296	CcSEcCtD
Irbesartan—Body temperature increased—Hydroxyurea—head and neck cancer	0.000283	0.00296	CcSEcCtD
Irbesartan—Leukopenia—Fluorouracil—head and neck cancer	0.000283	0.00295	CcSEcCtD
Irbesartan—Asthenia—Vinblastine—head and neck cancer	0.000282	0.00294	CcSEcCtD
Irbesartan—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000276	0.00288	CcSEcCtD
Irbesartan—Epistaxis—Docetaxel—head and neck cancer	0.000275	0.00288	CcSEcCtD
Irbesartan—Agranulocytosis—Docetaxel—head and neck cancer	0.000272	0.00285	CcSEcCtD
Irbesartan—Myalgia—Fluorouracil—head and neck cancer	0.000269	0.00281	CcSEcCtD
Irbesartan—Chest pain—Fluorouracil—head and neck cancer	0.000269	0.00281	CcSEcCtD
Irbesartan—Diarrhoea—Vinblastine—head and neck cancer	0.000269	0.00281	CcSEcCtD
Irbesartan—Discomfort—Fluorouracil—head and neck cancer	0.000266	0.00278	CcSEcCtD
Irbesartan—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000264	0.00276	CcSEcCtD
Irbesartan—Rhinitis—Docetaxel—head and neck cancer	0.000263	0.00274	CcSEcCtD
Irbesartan—Hepatitis—Docetaxel—head and neck cancer	0.000262	0.00274	CcSEcCtD
Irbesartan—Hypoaesthesia—Docetaxel—head and neck cancer	0.000261	0.00272	CcSEcCtD
Irbesartan—Pharyngitis—Docetaxel—head and neck cancer	0.00026	0.00272	CcSEcCtD
Irbesartan—Dizziness—Vinblastine—head and neck cancer	0.00026	0.00271	CcSEcCtD
Irbesartan—Urinary tract disorder—Docetaxel—head and neck cancer	0.000259	0.0027	CcSEcCtD
Irbesartan—Oedema peripheral—Docetaxel—head and neck cancer	0.000258	0.0027	CcSEcCtD
Irbesartan—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000258	0.00269	CcSEcCtD
Irbesartan—Oedema—Fluorouracil—head and neck cancer	0.000258	0.00269	CcSEcCtD
Irbesartan—Connective tissue disorder—Docetaxel—head and neck cancer	0.000257	0.00269	CcSEcCtD
Irbesartan—Asthenia—Hydroxyurea—head and neck cancer	0.000257	0.00269	CcSEcCtD
Irbesartan—Urethral disorder—Docetaxel—head and neck cancer	0.000257	0.00268	CcSEcCtD
Irbesartan—Infection—Fluorouracil—head and neck cancer	0.000256	0.00268	CcSEcCtD
Irbesartan—Nervous system disorder—Fluorouracil—head and neck cancer	0.000253	0.00264	CcSEcCtD
Irbesartan—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000252	0.00264	CcSEcCtD
Irbesartan—Visual impairment—Docetaxel—head and neck cancer	0.000252	0.00264	CcSEcCtD
Irbesartan—Tachycardia—Fluorouracil—head and neck cancer	0.000252	0.00263	CcSEcCtD
Irbesartan—Vomiting—Vinblastine—head and neck cancer	0.00025	0.00261	CcSEcCtD
Irbesartan—Headache—Vinblastine—head and neck cancer	0.000246	0.00257	CcSEcCtD
Irbesartan—Anorexia—Fluorouracil—head and neck cancer	0.000246	0.00257	CcSEcCtD
Irbesartan—Diarrhoea—Hydroxyurea—head and neck cancer	0.000245	0.00256	CcSEcCtD
Irbesartan—Flushing—Docetaxel—head and neck cancer	0.000243	0.00254	CcSEcCtD
Irbesartan—Cardiac disorder—Docetaxel—head and neck cancer	0.000243	0.00254	CcSEcCtD
Irbesartan—Hypotension—Fluorouracil—head and neck cancer	0.000241	0.00252	CcSEcCtD
Irbesartan—PTGS1—connective tissue—head and neck cancer	0.000238	0.0154	CbGeAlD
Irbesartan—Angiopathy—Docetaxel—head and neck cancer	0.000238	0.00248	CcSEcCtD
Irbesartan—Dizziness—Hydroxyurea—head and neck cancer	0.000237	0.00248	CcSEcCtD
Irbesartan—Immune system disorder—Docetaxel—head and neck cancer	0.000237	0.00247	CcSEcCtD
Irbesartan—Mediastinal disorder—Docetaxel—head and neck cancer	0.000236	0.00247	CcSEcCtD
Irbesartan—Chills—Docetaxel—head and neck cancer	0.000235	0.00246	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000235	0.00245	CcSEcCtD
Irbesartan—Arrhythmia—Docetaxel—head and neck cancer	0.000234	0.00245	CcSEcCtD
Irbesartan—Nausea—Vinblastine—head and neck cancer	0.000233	0.00244	CcSEcCtD
Irbesartan—Paraesthesia—Fluorouracil—head and neck cancer	0.000231	0.00242	CcSEcCtD
Irbesartan—Dyspnoea—Fluorouracil—head and neck cancer	0.00023	0.0024	CcSEcCtD
Irbesartan—Somnolence—Fluorouracil—head and neck cancer	0.000229	0.0024	CcSEcCtD
Irbesartan—Erythema—Docetaxel—head and neck cancer	0.000228	0.00238	CcSEcCtD
Irbesartan—Malnutrition—Docetaxel—head and neck cancer	0.000228	0.00238	CcSEcCtD
Irbesartan—Vomiting—Hydroxyurea—head and neck cancer	0.000228	0.00238	CcSEcCtD
Irbesartan—Dyspepsia—Fluorouracil—head and neck cancer	0.000227	0.00237	CcSEcCtD
Irbesartan—PTGS1—epithelium—head and neck cancer	0.000226	0.0146	CbGeAlD
Irbesartan—Rash—Hydroxyurea—head and neck cancer	0.000226	0.00236	CcSEcCtD
Irbesartan—Dermatitis—Hydroxyurea—head and neck cancer	0.000226	0.00236	CcSEcCtD
Irbesartan—Headache—Hydroxyurea—head and neck cancer	0.000224	0.00234	CcSEcCtD
Irbesartan—Decreased appetite—Fluorouracil—head and neck cancer	0.000224	0.00234	CcSEcCtD
Irbesartan—AGTR1—lymph node—head and neck cancer	0.000224	0.0144	CbGeAlD
Irbesartan—Dysgeusia—Docetaxel—head and neck cancer	0.000223	0.00233	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000223	0.00233	CcSEcCtD
Irbesartan—Pain—Fluorouracil—head and neck cancer	0.00022	0.0023	CcSEcCtD
Irbesartan—Muscle spasms—Docetaxel—head and neck cancer	0.000219	0.00229	CcSEcCtD
Irbesartan—Nausea—Hydroxyurea—head and neck cancer	0.000213	0.00222	CcSEcCtD
Irbesartan—Feeling abnormal—Fluorouracil—head and neck cancer	0.000212	0.00222	CcSEcCtD
Irbesartan—Anaemia—Docetaxel—head and neck cancer	0.000211	0.0022	CcSEcCtD
Irbesartan—Urticaria—Fluorouracil—head and neck cancer	0.000205	0.00214	CcSEcCtD
Irbesartan—Syncope—Docetaxel—head and neck cancer	0.000204	0.00214	CcSEcCtD
Irbesartan—Leukopenia—Docetaxel—head and neck cancer	0.000204	0.00213	CcSEcCtD
Irbesartan—Body temperature increased—Fluorouracil—head and neck cancer	0.000204	0.00213	CcSEcCtD
Irbesartan—Loss of consciousness—Docetaxel—head and neck cancer	0.0002	0.00209	CcSEcCtD
Irbesartan—PTGS1—trachea—head and neck cancer	0.0002	0.0129	CbGeAlD
Irbesartan—Cough—Docetaxel—head and neck cancer	0.000199	0.00208	CcSEcCtD
Irbesartan—Hypertension—Docetaxel—head and neck cancer	0.000197	0.00206	CcSEcCtD
Irbesartan—Chest pain—Docetaxel—head and neck cancer	0.000194	0.00203	CcSEcCtD
Irbesartan—Arthralgia—Docetaxel—head and neck cancer	0.000194	0.00203	CcSEcCtD
Irbesartan—Myalgia—Docetaxel—head and neck cancer	0.000194	0.00203	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000193	0.00201	CcSEcCtD
Irbesartan—Hypersensitivity—Fluorouracil—head and neck cancer	0.00019	0.00199	CcSEcCtD
Irbesartan—Dry mouth—Docetaxel—head and neck cancer	0.00019	0.00198	CcSEcCtD
Irbesartan—Oedema—Docetaxel—head and neck cancer	0.000186	0.00194	CcSEcCtD
Irbesartan—Anaphylactic shock—Docetaxel—head and neck cancer	0.000186	0.00194	CcSEcCtD
Irbesartan—Infection—Docetaxel—head and neck cancer	0.000185	0.00193	CcSEcCtD
Irbesartan—Shock—Docetaxel—head and neck cancer	0.000183	0.00191	CcSEcCtD
Irbesartan—CYP1A2—thyroid gland—head and neck cancer	0.000183	0.0118	CbGeAlD
Irbesartan—Nervous system disorder—Docetaxel—head and neck cancer	0.000182	0.00191	CcSEcCtD
Irbesartan—Pruritus—Fluorouracil—head and neck cancer	0.000182	0.00191	CcSEcCtD
Irbesartan—Thrombocytopenia—Docetaxel—head and neck cancer	0.000182	0.0019	CcSEcCtD
Irbesartan—Tachycardia—Docetaxel—head and neck cancer	0.000182	0.0019	CcSEcCtD
Irbesartan—Skin disorder—Docetaxel—head and neck cancer	0.000181	0.00189	CcSEcCtD
Irbesartan—Anorexia—Docetaxel—head and neck cancer	0.000177	0.00185	CcSEcCtD
Irbesartan—Diarrhoea—Fluorouracil—head and neck cancer	0.000176	0.00184	CcSEcCtD
Irbesartan—Hypotension—Docetaxel—head and neck cancer	0.000174	0.00182	CcSEcCtD
Irbesartan—Dizziness—Fluorouracil—head and neck cancer	0.00017	0.00178	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00017	0.00177	CcSEcCtD
Irbesartan—Paraesthesia—Docetaxel—head and neck cancer	0.000167	0.00175	CcSEcCtD
Irbesartan—Dyspnoea—Docetaxel—head and neck cancer	0.000166	0.00173	CcSEcCtD
Irbesartan—Somnolence—Docetaxel—head and neck cancer	0.000165	0.00173	CcSEcCtD
Irbesartan—Vomiting—Fluorouracil—head and neck cancer	0.000164	0.00171	CcSEcCtD
Irbesartan—Dyspepsia—Docetaxel—head and neck cancer	0.000164	0.00171	CcSEcCtD
Irbesartan—Rash—Fluorouracil—head and neck cancer	0.000163	0.0017	CcSEcCtD
Irbesartan—Dermatitis—Fluorouracil—head and neck cancer	0.000162	0.0017	CcSEcCtD
Irbesartan—Decreased appetite—Docetaxel—head and neck cancer	0.000162	0.00169	CcSEcCtD
Irbesartan—Headache—Fluorouracil—head and neck cancer	0.000161	0.00169	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000161	0.00168	CcSEcCtD
Irbesartan—Fatigue—Docetaxel—head and neck cancer	0.00016	0.00168	CcSEcCtD
Irbesartan—Pain—Docetaxel—head and neck cancer	0.000159	0.00166	CcSEcCtD
Irbesartan—Constipation—Docetaxel—head and neck cancer	0.000159	0.00166	CcSEcCtD
Irbesartan—PTGS1—thyroid gland—head and neck cancer	0.000158	0.0102	CbGeAlD
Irbesartan—Feeling abnormal—Docetaxel—head and neck cancer	0.000153	0.0016	CcSEcCtD
Irbesartan—Nausea—Fluorouracil—head and neck cancer	0.000153	0.0016	CcSEcCtD
Irbesartan—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000152	0.00159	CcSEcCtD
Irbesartan—Abdominal pain—Docetaxel—head and neck cancer	0.000147	0.00154	CcSEcCtD
Irbesartan—Body temperature increased—Docetaxel—head and neck cancer	0.000147	0.00154	CcSEcCtD
Irbesartan—PTGS1—head—head and neck cancer	0.00014	0.00905	CbGeAlD
Irbesartan—Hypersensitivity—Docetaxel—head and neck cancer	0.000137	0.00143	CcSEcCtD
Irbesartan—Asthenia—Docetaxel—head and neck cancer	0.000133	0.0014	CcSEcCtD
Irbesartan—Pruritus—Docetaxel—head and neck cancer	0.000132	0.00138	CcSEcCtD
Irbesartan—Diarrhoea—Docetaxel—head and neck cancer	0.000127	0.00133	CcSEcCtD
Irbesartan—Dizziness—Docetaxel—head and neck cancer	0.000123	0.00129	CcSEcCtD
Irbesartan—Vomiting—Docetaxel—head and neck cancer	0.000118	0.00124	CcSEcCtD
Irbesartan—Rash—Docetaxel—head and neck cancer	0.000117	0.00123	CcSEcCtD
Irbesartan—Dermatitis—Docetaxel—head and neck cancer	0.000117	0.00122	CcSEcCtD
Irbesartan—Headache—Docetaxel—head and neck cancer	0.000117	0.00122	CcSEcCtD
Irbesartan—CYP2D6—head—head and neck cancer	0.000115	0.00744	CbGeAlD
Irbesartan—Nausea—Docetaxel—head and neck cancer	0.000111	0.00116	CcSEcCtD
Irbesartan—PTGS1—lymph node—head and neck cancer	9.83e-05	0.00633	CbGeAlD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	6.69e-05	0.000492	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	6.66e-05	0.000489	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—DPYD—head and neck cancer	6.48e-05	0.000476	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—UROD—head and neck cancer	6.48e-05	0.000476	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—MAPK1—head and neck cancer	6.47e-05	0.000475	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GRP—head and neck cancer	6.47e-05	0.000475	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—head and neck cancer	6.42e-05	0.000472	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	6.38e-05	0.000469	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—head and neck cancer	6.37e-05	0.000468	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—MAPK1—head and neck cancer	6.36e-05	0.000467	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—head and neck cancer	6.36e-05	0.000467	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	6.33e-05	0.000465	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—PIK3CA—head and neck cancer	6.33e-05	0.000465	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	6.33e-05	0.000465	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	6.32e-05	0.000465	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	6.29e-05	0.000462	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT6—head and neck cancer	6.28e-05	0.000461	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	6.24e-05	0.000458	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	6.2e-05	0.000456	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	6.2e-05	0.000456	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	6.2e-05	0.000456	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	6.19e-05	0.000455	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—YAP1—head and neck cancer	6.15e-05	0.000452	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	6.05e-05	0.000444	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—AKT1—head and neck cancer	6.03e-05	0.000443	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	5.99e-05	0.000441	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	5.96e-05	0.000438	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	5.91e-05	0.000434	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—head and neck cancer	5.89e-05	0.000433	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KISS1—head and neck cancer	5.87e-05	0.000431	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—head and neck cancer	5.86e-05	0.000431	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	5.84e-05	0.000429	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—head and neck cancer	5.8e-05	0.000426	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—AKT1—head and neck cancer	5.79e-05	0.000425	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—AKT1—head and neck cancer	5.63e-05	0.000414	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—YAP1—head and neck cancer	5.56e-05	0.000408	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BCL2L1—head and neck cancer	5.53e-05	0.000407	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—PIK3CA—head and neck cancer	5.52e-05	0.000406	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	5.5e-05	0.000404	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—head and neck cancer	5.43e-05	0.000399	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—head and neck cancer	5.43e-05	0.000399	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	5.42e-05	0.000398	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	5.4e-05	0.000397	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	5.4e-05	0.000397	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—STAT3—head and neck cancer	5.38e-05	0.000395	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	5.33e-05	0.000392	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—UROD—head and neck cancer	5.32e-05	0.000391	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	5.32e-05	0.000391	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—UROD—head and neck cancer	5.27e-05	0.000387	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—AKT1—head and neck cancer	5.17e-05	0.00038	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—MAPK3—head and neck cancer	5.14e-05	0.000378	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	5.12e-05	0.000376	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	5.12e-05	0.000376	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—head and neck cancer	5.11e-05	0.000375	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—head and neck cancer	5.1e-05	0.000375	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	5.05e-05	0.000371	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.03e-05	0.000369	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	4.98e-05	0.000366	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—head and neck cancer	4.97e-05	0.000366	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—MAPK1—head and neck cancer	4.89e-05	0.000359	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GRP—head and neck cancer	4.83e-05	0.000355	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	4.77e-05	0.000351	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT6—head and neck cancer	4.69e-05	0.000345	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CASP8—head and neck cancer	4.52e-05	0.000333	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—head and neck cancer	4.51e-05	0.000331	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—UROD—head and neck cancer	4.51e-05	0.000331	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	4.49e-05	0.00033	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.42e-05	0.000325	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.38e-05	0.000322	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	4.17e-05	0.000306	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NAT2—head and neck cancer	4.16e-05	0.000306	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—YAP1—head and neck cancer	4.15e-05	0.000305	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	4.11e-05	0.000302	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—head and neck cancer	4.1e-05	0.000302	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2—head and neck cancer	4.09e-05	0.000301	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.09e-05	0.000301	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	3.95e-05	0.000291	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	3.9e-05	0.000287	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BCL2—head and neck cancer	3.88e-05	0.000285	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2—head and neck cancer	3.72e-05	0.000273	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TYMS—head and neck cancer	3.69e-05	0.000272	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—DPYD—head and neck cancer	3.65e-05	0.000268	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTM1—head and neck cancer	3.65e-05	0.000268	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GPX1—head and neck cancer	3.5e-05	0.000257	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.5e-05	0.000257	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—UROD—head and neck cancer	3.48e-05	0.000256	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—YAP1—head and neck cancer	3.47e-05	0.000255	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP1A1—head and neck cancer	3.46e-05	0.000254	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2L1—head and neck cancer	3.22e-05	0.000237	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PTEN—head and neck cancer	3.22e-05	0.000236	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—head and neck cancer	3.21e-05	0.000236	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NOTCH1—head and neck cancer	3.19e-05	0.000235	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—MAPK3—head and neck cancer	2.99e-05	0.00022	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—head and neck cancer	2.92e-05	0.000214	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.86e-05	0.00021	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—MAPK1—head and neck cancer	2.84e-05	0.000209	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—head and neck cancer	2.84e-05	0.000209	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.83e-05	0.000208	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MAPK3—head and neck cancer	2.75e-05	0.000202	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—head and neck cancer	2.72e-05	0.0002	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NAT2—head and neck cancer	2.69e-05	0.000198	CbGpPWpGaD
Irbesartan—JUN—Immune System—CASP8—head and neck cancer	2.64e-05	0.000194	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MAPK1—head and neck cancer	2.62e-05	0.000192	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—head and neck cancer	2.61e-05	0.000192	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—head and neck cancer	2.6e-05	0.000191	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.6e-05	0.000191	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOTCH1—head and neck cancer	2.5e-05	0.000184	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—head and neck cancer	2.47e-05	0.000181	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DPYD—head and neck cancer	2.36e-05	0.000173	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK3—head and neck cancer	2.35e-05	0.000172	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.33e-05	0.000171	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.3e-05	0.000169	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—head and neck cancer	2.28e-05	0.000168	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.27e-05	0.000167	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—head and neck cancer	2.27e-05	0.000167	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2—head and neck cancer	2.26e-05	0.000166	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—YAP1—head and neck cancer	2.24e-05	0.000165	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—MAPK1—head and neck cancer	2.23e-05	0.000164	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—head and neck cancer	2.23e-05	0.000164	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—head and neck cancer	2.22e-05	0.000163	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NAT2—head and neck cancer	2.21e-05	0.000162	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—head and neck cancer	2.2e-05	0.000161	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NAT2—head and neck cancer	2.19e-05	0.000161	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—head and neck cancer	2.14e-05	0.000157	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.13e-05	0.000157	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—head and neck cancer	2.1e-05	0.000154	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TYMS—head and neck cancer	2.08e-05	0.000153	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTEN—head and neck cancer	2.07e-05	0.000152	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—head and neck cancer	2.06e-05	0.000151	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTM1—head and neck cancer	2.06e-05	0.000151	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—head and neck cancer	2.02e-05	0.000148	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—head and neck cancer	1.99e-05	0.000146	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.99e-05	0.000146	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GPX1—head and neck cancer	1.97e-05	0.000145	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.97e-05	0.000145	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP1A1—head and neck cancer	1.95e-05	0.000143	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DPYD—head and neck cancer	1.94e-05	0.000142	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—head and neck cancer	1.94e-05	0.000142	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DPYD—head and neck cancer	1.92e-05	0.000141	CbGpPWpGaD
Irbesartan—JUN—Immune System—PTEN—head and neck cancer	1.87e-05	0.000138	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAT2—head and neck cancer	1.87e-05	0.000137	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOTCH1—head and neck cancer	1.87e-05	0.000137	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—head and neck cancer	1.87e-05	0.000137	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—head and neck cancer	1.85e-05	0.000136	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—head and neck cancer	1.85e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—YAP1—head and neck cancer	1.84e-05	0.000135	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—YAP1—head and neck cancer	1.82e-05	0.000134	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTEN—head and neck cancer	1.8e-05	0.000132	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—head and neck cancer	1.79e-05	0.000132	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—head and neck cancer	1.77e-05	0.00013	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—head and neck cancer	1.74e-05	0.000128	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—head and neck cancer	1.72e-05	0.000127	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.68e-05	0.000124	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—head and neck cancer	1.68e-05	0.000123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK1—head and neck cancer	1.68e-05	0.000123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—head and neck cancer	1.68e-05	0.000123	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—head and neck cancer	1.68e-05	0.000123	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DPYD—head and neck cancer	1.64e-05	0.000121	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTEN—head and neck cancer	1.62e-05	0.000119	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.6e-05	0.000118	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—head and neck cancer	1.6e-05	0.000118	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—head and neck cancer	1.58e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—YAP1—head and neck cancer	1.56e-05	0.000114	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK1—head and neck cancer	1.52e-05	0.000112	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—head and neck cancer	1.52e-05	0.000112	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.47e-05	0.000108	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—head and neck cancer	1.46e-05	0.000108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—head and neck cancer	1.46e-05	0.000107	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—head and neck cancer	1.45e-05	0.000107	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAT2—head and neck cancer	1.44e-05	0.000106	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—head and neck cancer	1.41e-05	0.000104	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—head and neck cancer	1.39e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.37e-05	0.000101	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—head and neck cancer	1.35e-05	9.91e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—head and neck cancer	1.34e-05	9.88e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—head and neck cancer	1.33e-05	9.76e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—head and neck cancer	1.32e-05	9.71e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK1—head and neck cancer	1.32e-05	9.69e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—head and neck cancer	1.32e-05	9.69e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—head and neck cancer	1.29e-05	9.46e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX1—head and neck cancer	1.27e-05	9.35e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—head and neck cancer	1.27e-05	9.31e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DPYD—head and neck cancer	1.27e-05	9.31e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP1A1—head and neck cancer	1.26e-05	9.26e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—head and neck cancer	1.25e-05	9.22e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—head and neck cancer	1.22e-05	8.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTEN—head and neck cancer	1.21e-05	8.9e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—YAP1—head and neck cancer	1.2e-05	8.83e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.19e-05	8.77e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—head and neck cancer	1.19e-05	8.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.17e-05	8.6e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—head and neck cancer	1.16e-05	8.52e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—head and neck cancer	1.14e-05	8.41e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—head and neck cancer	1.11e-05	8.13e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—head and neck cancer	1.1e-05	8.11e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—head and neck cancer	1.09e-05	8.04e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—head and neck cancer	1.09e-05	8.04e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.09e-05	8.02e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—head and neck cancer	1.08e-05	7.96e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.08e-05	7.95e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—head and neck cancer	1.08e-05	7.94e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—head and neck cancer	1.06e-05	7.78e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX1—head and neck cancer	1.04e-05	7.68e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX1—head and neck cancer	1.04e-05	7.61e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—head and neck cancer	1.03e-05	7.61e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.03e-05	7.6e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—head and neck cancer	1.03e-05	7.6e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.03e-05	7.6e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.03e-05	7.53e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.02e-05	7.5e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTEN—head and neck cancer	1.01e-05	7.43e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK1—head and neck cancer	9.85e-06	7.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—head and neck cancer	9.85e-06	7.24e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—head and neck cancer	9.35e-06	6.87e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—head and neck cancer	9.34e-06	6.87e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—head and neck cancer	9.24e-06	6.79e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX1—head and neck cancer	8.85e-06	6.5e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP1A1—head and neck cancer	8.76e-06	6.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—head and neck cancer	8.55e-06	6.28e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	8.42e-06	6.19e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—head and neck cancer	8.27e-06	6.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—head and neck cancer	7.91e-06	5.81e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—head and neck cancer	7.49e-06	5.5e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—head and neck cancer	7.21e-06	5.3e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.2e-06	5.29e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—head and neck cancer	7.13e-06	5.24e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—head and neck cancer	7.13e-06	5.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—head and neck cancer	6.98e-06	5.13e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX1—head and neck cancer	6.83e-06	5.02e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP1A1—head and neck cancer	6.76e-06	4.97e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTEN—head and neck cancer	6.53e-06	4.8e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—head and neck cancer	6.15e-06	4.52e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—head and neck cancer	6.1e-06	4.48e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—head and neck cancer	5.83e-06	4.28e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTEN—head and neck cancer	5.36e-06	3.94e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTEN—head and neck cancer	5.32e-06	3.91e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—head and neck cancer	5.21e-06	3.83e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—head and neck cancer	4.61e-06	3.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTEN—head and neck cancer	4.54e-06	3.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—head and neck cancer	4.02e-06	2.95e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.78e-06	2.78e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—head and neck cancer	3.76e-06	2.77e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.75e-06	2.76e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTEN—head and neck cancer	3.51e-06	2.58e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—head and neck cancer	3.2e-06	2.36e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—head and neck cancer	3.09e-06	2.27e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—head and neck cancer	3.06e-06	2.25e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—head and neck cancer	2.62e-06	1.92e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.47e-06	1.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—head and neck cancer	2.02e-06	1.49e-05	CbGpPWpGaD
